| Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia. | |
| | |
MedLine Citation:
|
PMID: 21523727 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The impact of FMS-like tyrosine kinase 3 (FLT3) mutations and mutation burden among cytogenetic subgroups of patients with acute myeloid leukemia (AML) other than normal karyotype (NK) AML is unclear. METHODS: Patients with newly diagnosed AML were divided among 3 cytogenetic subgroups: core binding factor (CBF) AML, NK-AML, and poor-risk AML. RESULTS: In total, 481 patients were included: 13% had, CBF-AML, 57% had NK-AML, and 30% had poor risk AML, and the frequency of any FLT3 mutations was 20%, 32%, and 7.6% in the respective cytogenetic subgroups. FLT3 mutation did not have an impact on event-free survival (EFS) in patients with CBF-AML (P = .84) and poor-risk AML (P = .37). In patients with NK-AML, EFS was worse in the FLT3-internal tandem duplication (ITD) group (20 weeks vs 41 weeks; P < .00,001) but not in the FLT3-tyrosine kinase domain (TKD) point mutation group (61 weeks vs 41 weeks; P = .15). Worse EFS and overall survival (OS) were observed among patients with NK-AML and higher FLT3-ITD burden but not among patients with FLT3-TKD mutation. In multivariate analysis, FLT3-ITD mutation was prognostic of EFS in patients with NK-AML (hazard ratio, 3.1; P = .03). CONCLUSIONS: FLT3 mutations did not have a prognostic impact in patients with AML who had good-risk and poor-risk karyotypes. In patients with NK-AML, FLT3-ITD mutations led to worse survival, which was even worse among patients who had high mutation burden. |
| | |
Authors:
|
Fabio P S Santos; Dan Jones; Wei Qiao; Jorge E Cortes; Farhad Ravandi; Elihu E Estey; Dushyant Verma; Hagop Kantarjian; Gautam Borthakur |
Related Documents
:
|
21353607 - The genetic heterogeneity of β-globin gene defects in sicily reflects the historic pop... 21301777 - Frequency of platelet type versus type 2b von willebrand disease. an international regi... 21118387 - Bsaxi/rflp analysis of initial or selectively reamplified pcr product is unreliable in ... 20044737 - Synopsis and data synthesis of genetic association studies in hypertension for the adre... 7750117 - Detection of dna mutations in acid formalin-fixed paraffin-embedded archival tumor spec... 21353607 - The genetic heterogeneity of β-globin gene defects in sicily reflects the historic pop... |
Publication Detail:
|
Type: Evaluation Studies; Journal Article Date: 2010-11-29 |
Journal Detail:
|
Title: Cancer Volume: 117 ISSN: 0008-543X ISO Abbreviation: Cancer Publication Date: 2011 May |
Date Detail:
|
Created Date: 2011-04-27 Completed Date: 2011-06-14 Revised Date: 2011-07-27 |
Medline Journal Info:
|
Nlm Unique ID: 0374236 Medline TA: Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 2145-55 Citation Subset: AIM; IM |
Copyright Information:
|
2010 American Cancer Society. |
Affiliation:
|
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Chromosome Aberrations Core Binding Factors / genetics Disease-Free Survival Female Genetic Markers Genotype Humans Leukemia, Myeloid, Acute / genetics*, mortality Male Middle Aged Mutation Prognosis Retrospective Studies Risk fms-Like Tyrosine Kinase 3 / genetics* |
| Chemical | |
Reg. No./Substance:
|
0/Core Binding Factors; 0/Genetic Markers; EC 2.7.10.1/fms-Like Tyrosine Kinase 3 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple my...
Next Document: Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia p...